TRCT
CLDI icon

Tower Research Capital (TRC)’s Calidi Biotherapeutics CLDI Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333 Sell
1,396
-1,378
-50% -$1.03K ﹤0.01% 4908
2025
Q4 		$3.25K Buy
+2,774
New +$4.08K ﹤0.01% 4396
2025
Q3 		– Sell
-745
Closed -$2.06K – 5260
2025
Q2 		$2.06K Buy
745
+319
+75% +$1.55K ﹤0.01% 4707
2025
Q1 		$2.9K Buy
+426
New +$4.86K ﹤0.01% 4491
2024
Q4 		– Sell
-306
Closed -$4.18K – 5720
2024
Q3 		$4.18K Buy
306
+236
+337% +$4.11K ﹤0.01% 4644
2024
Q2 		$1.68K Sell
70
-77
-52% -$2.46K ﹤0.01% 5107
2024
Q1 		$9.99K Buy
+147
New +$15K ﹤0.01% 3766
2023
Q4 		– Hold
0
– – – 5881

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s CLDI Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Calidi Biotherapeutics (CLDI) stake by 50% in Q1 2026, selling an estimated $1.03K and leaving 1,396 shares worth $333. The position accounts for ﹤0.01% of the portfolio, ranked #4908.

Tower Research Capital (TRC) first reported a position in CLDI in Q1 2024 and has held it in 7 quarters since. The position peaked at $9.99K in Q1 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • Tower Research Capital (TRC) held 1,396 shares of Calidi Biotherapeutics worth $333 as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,378 Calidi Biotherapeutics shares in Q1 2026, an estimated $1.03K.
  • Calidi Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4908 holding.
  • Tower Research Capital (TRC) first reported a position in Calidi Biotherapeutics in Q1 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Calidi Biotherapeutics position peaked at $9.99K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.